Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

No Changes in Immune Activation Phenotypes, Response to Antigen, or CD8+ T-cell Mediated HIV Suppression in Transplant Recipients Receiving Immunosuppression

Go back to Resources

No Changes in Immune Activation Phenotypes, Response to Antigen, or CD8+ T-cell Mediated HIV Suppression in Transplant Recipients Receiving Immunosuppression

Authors:

Location:

Go back to Resources

No Benefit of 1log T-cell Depletion on Chronic Graft vs Host Disease (cGVHD):Results of a Multi-Center Randomized Trial in 404 Recipients of Unrelated Donor Bone Marrow Transplantation (UBMT)

Go back to Resources

No Benefit of 1log T-cell Depletion on Chronic Graft vs Host Disease (cGVHD):Results of a Multi-Center Randomized Trial in 404 Recipients of Unrelated Donor Bone Marrow Transplantation (UBMT)

Authors:

Location:

Go back to Resources

National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 10

Go back to Resources

National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 10

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Mortality in the Age-Related Eye Disease Study: Associations with Lens Opacity and Cataract Surgery

Go back to Resources

Mortality in the Age-Related Eye Disease Study: Associations with Lens Opacity and Cataract Surgery

Authors:

Location:

Go back to Resources

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

Go back to Resources

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

International Multicenter Trial of Islet Transplantation Using the Edmonton Protocol in Patients with Type 1 Diabetes

Go back to Resources

International Multicenter Trial of Islet Transplantation Using the Edmonton Protocol in Patients with Type 1 Diabetes

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Macular Edema Study (PKC-DMES)

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Macular Edema Study (PKC-DMES)

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C b Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Go back to Resources

Initial results of the Protein Kinase C b Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Authors:

Location:

Go back to Resources

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Go back to Resources

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 140
  • Page 141
  • Page 142
  • Page 143
  • Current page 144
  • Page 145
  • Page 146
  • Page 147
  • Page 148
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification